As of 2026-05-27, the Intrinsic Value of Jafron Biomedical Co Ltd (300529.SZ) is 12.44 CNY. This 300529.SZ valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 18.36 CNY, the upside of Jafron Biomedical Co Ltd is -32.30%.
The range of the Intrinsic Value is 9.87 - 17.77 CNY
Based on its market price of 18.36 CNY and our intrinsic valuation, Jafron Biomedical Co Ltd (300529.SZ) is overvalued by 32.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 9.87 - 17.77 | 12.44 | -32.3% |
| DCF (Growth 10y) | 10.75 - 18.41 | 13.27 | -27.7% |
| DCF (EBITDA 5y) | 24.14 - 32.55 | 26.51 | 44.4% |
| DCF (EBITDA 10y) | 20.85 - 30.05 | 23.80 | 29.6% |
| Fair Value | 3.53 - 3.53 | 3.53 | -80.75% |
| P/E | 15.22 - 27.80 | 19.87 | 8.2% |
| EV/EBITDA | 18.43 - 24.42 | 19.89 | 8.4% |
| EPV | 5.62 - 6.95 | 6.28 | -65.8% |
| DDM - Stable | 5.11 - 13.51 | 9.31 | -49.3% |
| DDM - Multi | 8.52 - 15.65 | 10.87 | -40.8% |
| Market Cap (mil) | 14,662.48 |
| Beta | 1.00 |
| Outstanding shares (mil) | 798.61 |
| Enterprise Value (mil) | 13,411.84 |
| Market risk premium | 6.13% |
| Cost of Equity | 10.20% |
| Cost of Debt | 5.00% |
| WACC | 9.74% |